Biogen price target raised to $315 from $300 at Cowen

Cowen analyst Phil Nadeau raised the firm’s price target on Biogen to $315 from $300 and keeps an Outperform rating on the shares. The analyst said with both revenue and EPS expected to decline 2023 is largely a year of transition ahead of the launches of Leqembi and zuranolone. We are optimistic that their adoption will return Biogen to growth.